The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients

Pregabalin is increasingly being used as a first-line treatment for symptomatic control of restless legs syndrome (RLS). This study aimed to evaluate the efficacy and safety of pregabalin as add-on therapy in RLS patients already taking dopamine agonists (DA) but still in need of further management....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyoeun Bae, Yong Won Cho, Keun Tae Kim, Richard P. Allen, Christopher J. Earley
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	restless legs syndrome pregabalin dopamine agonists treatment add-on Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9807968267f44f298608ad9d76652458
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9807968267f44f298608ad9d76652458
record_format	dspace
spelling	oai:doaj.org-article:9807968267f44f298608ad9d766524582021-12-01T12:48:48ZThe Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients1664-229510.3389/fneur.2021.786408https://doaj.org/article/9807968267f44f298608ad9d766524582021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fneur.2021.786408/fullhttps://doaj.org/toc/1664-2295Pregabalin is increasingly being used as a first-line treatment for symptomatic control of restless legs syndrome (RLS). This study aimed to evaluate the efficacy and safety of pregabalin as add-on therapy in RLS patients already taking dopamine agonists (DA) but still in need of further management. Patients with idiopathic RLS were enrolled, and all had already been prescribed DA for at least 3 months but still had either persistent symptoms, side effects, or comorbid insomnia. An initial dose of 75 mg pregabalin was begun, adjusted as needed, and maintained at a stable dose for 4 weeks, followed by observation for a total of 8 weeks. RLS symptoms and insomnia scores were evaluated before and after add-on pregabalin treatment. Patients were monitored for side effects that could be attributed to pregabalin. A total of 32 RLS patients were enrolled, and 20 subjects remained until the endpoint. After the pregabalin add-on, the mean IRLS score showed significant improvement compared to the baseline (p < 0.001). The insomnia severity index score also improved (p = 0.036), and no serious adverse effects were observed. Our preliminary data suggests the potential for pregabalin as an add-on therapy to DA with regards to both efficacy and safety in patients who have inadequate RLS improvement.Hyoeun BaeYong Won ChoKeun Tae KimRichard P. AllenChristopher J. EarleyFrontiers Media S.A.articlerestless legs syndromepregabalindopamine agoniststreatmentadd-onNeurology. Diseases of the nervous systemRC346-429ENFrontiers in Neurology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	restless legs syndrome pregabalin dopamine agonists treatment add-on Neurology. Diseases of the nervous system RC346-429
spellingShingle	restless legs syndrome pregabalin dopamine agonists treatment add-on Neurology. Diseases of the nervous system RC346-429 Hyoeun Bae Yong Won Cho Keun Tae Kim Richard P. Allen Christopher J. Earley The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
description	Pregabalin is increasingly being used as a first-line treatment for symptomatic control of restless legs syndrome (RLS). This study aimed to evaluate the efficacy and safety of pregabalin as add-on therapy in RLS patients already taking dopamine agonists (DA) but still in need of further management. Patients with idiopathic RLS were enrolled, and all had already been prescribed DA for at least 3 months but still had either persistent symptoms, side effects, or comorbid insomnia. An initial dose of 75 mg pregabalin was begun, adjusted as needed, and maintained at a stable dose for 4 weeks, followed by observation for a total of 8 weeks. RLS symptoms and insomnia scores were evaluated before and after add-on pregabalin treatment. Patients were monitored for side effects that could be attributed to pregabalin. A total of 32 RLS patients were enrolled, and 20 subjects remained until the endpoint. After the pregabalin add-on, the mean IRLS score showed significant improvement compared to the baseline (p < 0.001). The insomnia severity index score also improved (p = 0.036), and no serious adverse effects were observed. Our preliminary data suggests the potential for pregabalin as an add-on therapy to DA with regards to both efficacy and safety in patients who have inadequate RLS improvement.
format	article
author	Hyoeun Bae Yong Won Cho Keun Tae Kim Richard P. Allen Christopher J. Earley
author_facet	Hyoeun Bae Yong Won Cho Keun Tae Kim Richard P. Allen Christopher J. Earley
author_sort	Hyoeun Bae
title	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
title_short	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
title_full	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
title_fullStr	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
title_full_unstemmed	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients
title_sort	safety and efficacy of pregabalin add-on therapy in restless legs syndrome patients
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9807968267f44f298608ad9d76652458
work_keys_str_mv	AT hyoeunbae thesafetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT yongwoncho thesafetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT keuntaekim thesafetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT richardpallen thesafetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT christopherjearley thesafetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT hyoeunbae safetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT yongwoncho safetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT keuntaekim safetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT richardpallen safetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients AT christopherjearley safetyandefficacyofpregabalinaddontherapyinrestlesslegssyndromepatients
_version_	1718405189379031040

The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients

Ejemplares similares